At what enterprise value was PÉTERS SURGICAL acquired in 2024?

During the acquisition of PÉTERS SURGICAL by ADVANCED MEDICAL SOLUTIONS GROUP in 2024, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 13.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of PÉTERS SURGICAL when it was acquired by ADVANCED MEDICAL SOLUTIONS GROUP?

The estimated EV/EBITDA multiple for PÉTERS SURGICAL is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 13.4x. Join our community for free to access full valuation data and industry trends.

What was the revenue of PÉTERS SURGICAL at the time of the deal?

The revenue of PÉTERS SURGICAL at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of PÉTERS SURGICAL during the acquisition?

PÉTERS SURGICAL's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the PÉTERS SURGICAL acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PÉTERS SURGICAL deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://peters-surgical.fr/eurazeo-cede-le-capital-de-peters-surgical-a-advance-medical-solutions/

← DATABASE

Home Database Healthcare & PharmaPÉTERS SURGICAL

03/2024

PÉTERS SURGICAL

Acquired by

ADVANCED MEDICAL SOLUTIONS GROUP

FRANCE Life Sciences / Medical Devices / Medical Consumables EV 100M - 350M EUR

PÉTERS SURGICAL acquired by ADVANCED MEDICAL SOLUTIONS GROUP

FRANCE Life Sciences / Medical Devices / Medical Consumables EV 100M - 350M EUR

Context

The acquisition of Peters Surgical by Advanced Medical Solutions Group plc is a strategic move to expand AMS's portfolio of surgical products and strengthen its presence in the global wound closure and tissue repair market. The transaction will enable Peters Surgical to benefit from complementary product portfolios, sales forces, commercial presence, and distribution networks. The acquisition is expected to create a leading player in the advanced wound closure and surgical closure market, with a comprehensive portfolio of products and a strong global presence. The combined entity will have increased direct sales capabilities in key markets, including France, the USA, Germany, India, Poland, and Belgium, and will be well-positioned to capitalize on cross-selling and upselling opportunities. The acquisition is subject to approval by the French authorities and is expected to be completed in 2024.

PÉTERS SURGICAL, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a level LOGIN the average currently observed in the Healthcare & Pharma sector (13.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Péters Surgical is a French company that designs, manufactures, and distributes a range of single-use medical devices for operating rooms. The company's primary product lines include surgical sutures, wall reinforcements, and drains. Founded in 1926 and based in Bobigny, Péters Surgical has established a strong presence in the French market and exports its products to over 75 countries worldwide. The company's business model is centered on building close relationships with its clients, including public hospitals and private clinics, and it has developed a network of agents and distributors to support its international sales efforts. With a workforce of approximately 350 employees, Péters Surgical has demonstrated significant growth in recent years, with revenue increasing from 24 million euros in 2009 to 37 million euros in 2012. The company's products are designed to meet the specific needs of surgical professionals, and its commitment to quality and innovation has enabled it to establish a strong reputation in the medical device industry.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2023

2022

Other operations with PÉTERS SURGICAL

Date	Acquirer	Target	Country	Sector	Deal Context
06/2013	EURAZEO	PÉTERS SURGICAL	FRANCE	Life Sciences	The acquisition of Péters Surgical by Eurazeo PME is a strategic move that reflects the investment firm's commitment to supporting the growth and development of medium-sized enterprises in the healthcare sector. With its strong track record of investing in medical device companies, Eurazeo PME will provide Péters Surgical with the financial and strategic support it needs to continue expanding its product offerings and increasing its international presence. The deal is expected to be completed by the end of July 2013, with Eurazeo PME acquiring approximately 90% of Péters Surgical's capital. The company's management team, including President and CEO Jean-Marc Chalot, will retain a significant stake in the business and will continue to play a key role in driving its growth and development. The acquisition is expected to provide Péters Surgical with the resources it needs to pursue its strategic objectives, including expanding its product lines and increasing its presence in emerging markets. With its strong reputation for quality and innovation, Péters Surgical is well-positioned to become a leading player in the global medical device industry, and Eurazeo PME's support will be instrumental in helping the company achieve its full potential.

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PÉTERS SURGICAL by ADVANCED MEDICAL SOLUTIONS GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: péters surgical

Acquirer: advanced medical solutions group